Xanthone
Based on 3 publication(s) in Google Scholar
Xanthone is a monoamine oxidase A (MAO-A) inhibitor with an IC50 of 0.84 µM. Xanthon inhibits Norepinephrine (HY-13715) and high-K+-induced vasoconstriction with IC50 values of 60.26 μM and 82.9 μM, respectively. Xanthon increases intracellular cyclic adenosine 3′,5′-monophosphate (cAMP) content and blocks Ca2+ channels. Xanthone is the scaffold of several pharmacologically active compounds.
For research use only. We do not sell to patients.
- Purity: 99.97%
- CAS No.: 90-47-1
- Formula: C13H8O2
- Molecular Weight:196.21
-
Storage:
Store at room temperature 3 years.
In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Xanthone
MoreAll Calcium Channel Isoforms
More
Biological Activity
|
MAO-A 0.84 μM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BV-2 | IC50 |
21.15 μM
Compound: Xanthone
|
Antiinflammatory activity in LPS-induced mouse BV-2 cells assessed as inhibition of NO production incubated for 24 hrs by Griess reagent based analysis
Antiinflammatory activity in LPS-induced mouse BV-2 cells assessed as inhibition of NO production incubated for 24 hrs by Griess reagent based analysis
|
[PMID: 39088998] |
| DU-145 | IC50 |
>500 μM
Compound: 3
|
Cytotoxicity against human DU145 cells after 48 hrs
Cytotoxicity against human DU145 cells after 48 hrs
|
[PMID: 20129790] |
| HeLa | IC50 |
>500 μM
Compound: 3
|
Cytotoxicity against human HeLa cells after 48 hrs
Cytotoxicity against human HeLa cells after 48 hrs
|
[PMID: 20129790] |
| MCF7 | IC50 |
>500 μM
Compound: 3
|
Cytotoxicity against human MCF7 cells after 48 hrs
Cytotoxicity against human MCF7 cells after 48 hrs
|
[PMID: 20129790] |
Xanthone relaxes the Norepinephrine (HY-13715)-induced contraction of rat thoracic aorta. The Norepinephrine and high-K+-induced vasoconstriction is inhibited dose dependently in aorta pretreated with Xanthone with IC50 values of 60.26 μM and 82.9 μM, respectively[1].
Xanthone concentration dependently inhibits the Ca2+ influx induced by either norepinephrine or high-K+, suggesting that Xanthone might act as a blocker of both receptor-operated and voltage-dependent Ca2+ channels[1].
Xanthone causes an increase in the level of intracellular cyclic adenosine 3′,5′-monophosphate (cAMP), but not cyclic guanosine 3′,5′-monophosphate (cGMP) content[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 90-47-1
-
Appearance Solid
-
Molecular Weight 196.21
-
Formula C13H8O2
-
Color White to off-white
-
SMILES
O=C1C2=C(OC3=C1C=CC=C3)C=CC=C2
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Store at room temperature 3 years
In solvent -80°C 2 years -20°C 1 year
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cell Metab
Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry. [Abstract]2022 Mar 1;34(3):424-440.e7. PMID: 35150639 -
Platelets
2025 Dec;36(1):2597777. PMID: 41399133 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607
Solvent & Solubility
DMSO : 10 mg/mL (50.97 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (459 KB)
- English - EN (459 KB)
- Français - FR (459 KB)
- Deutsch - DE (459 KB)
- Norwegian - NO (459 KB)
- Español - ES (459 KB)
- Swedish - SV (459 KB)
- Italian - IT (459 KB)
- Korean - KR (459 KB)
- Portuguese - PT (459 KB)
-
Handling Instructions (2659 KB)
References
[1]. Cheng YW, et al. Mechanism of vasorelaxation of thoracic aorta caused by xanthone. Eur J Pharmacol. 1997 Oct 1;336(1):23-8. [Content Brief]
[2]. El-Seedi HR, et al. Recent insights into the biosynthesis and biological activities of natural xanthones. Curr Med Chem. 2010;17(9):854-901. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.0966 mL | 25.4829 mL | 50.9658 mL | 127.4145 mL |
| 5 mM | 1.0193 mL | 5.0966 mL | 10.1932 mL | 25.4829 mL | |
| 10 mM | 0.5097 mL | 2.5483 mL | 5.0966 mL | 12.7415 mL | |
| 15 mM | 0.3398 mL | 1.6989 mL | 3.3977 mL | 8.4943 mL | |
| 20 mM | 0.2548 mL | 1.2741 mL | 2.5483 mL | 6.3707 mL | |
| 25 mM | 0.2039 mL | 1.0193 mL | 2.0386 mL | 5.0966 mL | |
| 30 mM | 0.1699 mL | 0.8494 mL | 1.6989 mL | 4.2472 mL | |
| 40 mM | 0.1274 mL | 0.6371 mL | 1.2741 mL | 3.1854 mL | |
| 50 mM | 0.1019 mL | 0.5097 mL | 1.0193 mL | 2.5483 mL |